---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-26-000052"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2026-06-18T20:03:10+00:00"
generated_at: "2026-06-18T20:04:20.017900+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Zentalis shareholders elect two Class III directors, ratify auditor, approve say-on-pay at 2026 annual meeting

## Summary
- David Johnson and Jan Skvarka elected as Class III directors with 20.7M and 23.5M votes for, respectively.
- Ratification of Ernst & Young as auditor for FY2026 passed with 49.3M votes for (99.7% of votes cast).
- Advisory say-on-pay proposal approved with 21.9M for vs 10.9M against, excluding broker non-votes.
- Approximately 69.5% of outstanding shares (49.5M) were represented at the meeting.

## SEC filing metadata
- accession: 0001725160-26-000052
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2026-06-18T20:03:10+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000052/0001725160-26-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000052/zntl-20260616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-26-000052
- JSON: https://secwatch.observer/filing/0001725160-26-000052.json
- Plain text: https://secwatch.observer/filing/0001725160-26-000052.txt

## Key facts
- Shareholder Votes
  Zentalis Pharmaceuticals, Inc. shareholders approved Election of two Class III directors to serve until the 2029 Annual Meeting of Stockholders at the 2026-06-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: Item 1 — Election of two Class III directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes David Johnson 20,711,869 12,215,784 16,526,113 Jan Skvarka, Ph.D. 23,497,184 9,430,469 16,526,113
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000052/0001725160-26-000052-index.htm
- Shareholder Votes
  Zentalis Pharmaceuticals, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-16 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 21,949,844 10,930,673 47,136 16,526,113
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000052/0001725160-26-000052-index.htm
- Shareholder Votes
  Zentalis Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-16 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 49,321,951 13,557 118,258 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000052/0001725160-26-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.